CoreRX, Inc.

Starton Therapeutics Partners with Bend Bioscience to Develop Oral Sustained-Release Lenalidomide for Multiple Myeloma

- Starton Therapeutics has entered a collaboration agreement with Bend Bioscience to develop STAR-LLD, an oral sustained-release formulation of lenalidomide designed to improve tolerability and efficacy in multiple myeloma treatment. - Preclinical studies demonstrated that STAR-LLD achieved 100% overall response rate with continuous delivery compared to 0% with standard daily dosing, while also showing 80% tumor shrinkage over 28 days. - A Phase 1b clinical study in six relapsed/refractory multiple myeloma patients showed all participants achieved objective responses with no grade >2 drug-related hematologic toxicity through 12 treatment cycles. - The partnership leverages Bend's controlled release formulation expertise to optimize STAR-LLD's performance and scalability for potential commercial manufacturing.